[Form 4] Xeris Biopharma Holdings, Inc. Insider Trading Activity
Insider sale of XERS common stock reduced holdings: Director John Johnson sold 107,500 shares of Xeris Biopharma common stock on 08/13/2025 at a weighted average price of $7.3159 per share, leaving him with 833,483 shares beneficially owned. The Form 4 lists the sale as a direct disposition and notes the reported price is a weighted average reflecting multiple trades priced between $7.250 and $7.420. No derivative transactions or additional changes in indirect ownership are reported. The filing was signed by an attorney-in-fact on behalf of the reporting person.
Vendita interna di azioni ordinarie XERS ha ridotto la partecipazione: Il consigliere John Johnson ha venduto 107.500 azioni ordinarie di Xeris Biopharma il 13/08/2025 a un prezzo medio ponderato di $7,3159 per azione, rimanendo con 833.483 azioni di propriet脿 effettiva. Il Modulo 4 indica la vendita come una cessione diretta e precisa che il prezzo riportato 猫 una media ponderata risultante da pi霉 operazioni effettuate tra $7,250 e $7,420. Non sono riportate operazioni su derivati n茅 variazioni aggiuntive nella propriet脿 indiretta. La dichiarazione 猫 stata firmata da un procuratore in nome della persona che ha presentato la comunicazione.
Venta interna de acciones ordinarias de XERS redujo la tenencia: El director John Johnson vendi贸 107.500 acciones ordinarias de Xeris Biopharma el 13/08/2025 a un precio medio ponderado de $7,3159 por acci贸n, quedando con 833.483 acciones de propiedad beneficiosa. El Formulario 4 indica la venta como una disposici贸n directa y se帽ala que el precio informado es un promedio ponderado que refleja m煤ltiples operaciones con precios entre $7,250 y $7,420. No se informan transacciones con derivados ni cambios adicionales en la propiedad indirecta. La presentaci贸n fue firmada por un apoderado en nombre de la persona que presenta el informe.
XERS 氤错喌欤� 雮措秬鞛� 毵る弰搿� 氤挫湢 歆�攵� 於曥唽: 鞚挫偓 John Johnson鞚� 2025-08-13鞐� Xeris Biopharma 氤错喌欤� 107,500欤茧ゼ 欤茧嫻 臧�欷戫弶攴犼皜瓴� $7.3159鞐� 毵る弰頃橃棳, 斓滌鞝侅溂搿� 833,483欤检潣 鞁れ唽鞙� 歆�攵勳潉 氤挫湢頃橁矊 霅橃棃鞀惦媹雼�. 鞝滌稖霅� Form 4電� 頃措嫻 毵る弰毳� 歆侅爲 觳橂秳鞙茧 旮办灛頃橁碃 氤搓碃霅� 臧�瓴╈潃 $7.250鞐愳劀 $7.420 靷澊鞚� 鞐煬 瓯半灅毳� 氚橃榿頃� 臧�欷戫弶攴犾瀯鞚� 氇呾嫓頃╇媹雼�. 韺岇儩靸來拡 瓯半灅雮� 臧勳爲 靻岇湢甓岇潣 於旉皜 氤�瓴届潃 氤搓碃霅橃 鞎婌晿鞀惦媹雼�. 鞝滌稖 靹滊電� 氤搓碃鞚胳潉 雽�鞁犿暣 鞙勳瀯 雼措嫻 氤�順胳偓臧� 靹滊獏頄堨姷雼堧嫟.
Vente interne d'actions ordinaires XERS a r茅duit la d茅tention聽: Le directeur John Johnson a vendu 107听500 actions ordinaires de Xeris Biopharma le 13/08/2025 au prix moyen pond茅r茅 de $7,3159 par action, le laissant avec 833听483 actions d茅tenues 脿 titre b茅n茅ficiaire. Le formulaire 4 indique la vente comme une cession directe et pr茅cise que le prix rapport茅 est une moyenne pond茅r茅e refl茅tant plusieurs transactions comprises entre $7,250 et $7,420. Aucune op茅ration sur d茅riv茅s ni modification suppl茅mentaire de la d茅tention indirecte n'est signal茅e. Le d茅p么t a 茅t茅 sign茅 par un mandataire au nom de la personne d茅clarante.
Insider-Verkauf von XERS-Stammaktien verringerte Beteiligung: Direktor John Johnson verkaufte am 13.08.2025 107.500 Xeris Biopharma-Stammaktien zu einem gewichteten Durchschnittspreis von $7,3159 je Aktie und bleibt mit 833.483 Anteilen wirtschaftlich berechtigt. Das Formular 4 f眉hrt den Verkauf als direkte Ver盲u脽erung auf und stellt klar, dass der gemeldete Preis ein gewichteter Durchschnitt aus mehreren Trades zwischen $7,250 und $7,420 ist. Es werden keine Derivatgesch盲fte oder weiteren 脛nderungen der indirekten Beteiligung gemeldet. Die Einreichung wurde von einem Bevollm盲chtigten im Namen der meldenden Person unterschrieben.
- None.
- Director John Johnson executed a direct sale of 107,500 XERS shares, reducing his beneficial ownership to 833,483 shares.
- The sale may represent insider liquidity; the filing does not state a Rule 10b5-1 plan or other rationale for the disposition.
Insights
TL;DR: A director sold 107,500 XERS shares at ~$7.32, reducing direct holdings to 833,483 shares.
The sale is a straightforward, non-derivative disposition reported under Section 16. The transaction was executed in multiple trades at prices between $7.25 and $7.42, producing a weighted average price of $7.3159. Without concurrent disclosure of intentions, planned Rule 10b5-1 activity, or size relative to outstanding shares, this single reported sale is a data point rather than definitive evidence of material change in company outlook. Investors should view this as routine insider liquidity unless corroborated by additional filings or company events.
TL;DR: Director-reported sale is properly disclosed; documentation notes weighted-average pricing across multiple trades.
The Form 4 correctly identifies the reporting person as a director and records a direct disposition. The explanation clarifies the weighted-average price range and offers to provide transaction-level pricing on request, which supports disclosure transparency. There is no indication in the filing of an amendment, a Section 16 exemption, or a Rule 10b5-1 plan election tied to this sale. From a governance compliance standpoint, the filing meets Section 16 reporting requirements as presented.
Vendita interna di azioni ordinarie XERS ha ridotto la partecipazione: Il consigliere John Johnson ha venduto 107.500 azioni ordinarie di Xeris Biopharma il 13/08/2025 a un prezzo medio ponderato di $7,3159 per azione, rimanendo con 833.483 azioni di propriet脿 effettiva. Il Modulo 4 indica la vendita come una cessione diretta e precisa che il prezzo riportato 猫 una media ponderata risultante da pi霉 operazioni effettuate tra $7,250 e $7,420. Non sono riportate operazioni su derivati n茅 variazioni aggiuntive nella propriet脿 indiretta. La dichiarazione 猫 stata firmata da un procuratore in nome della persona che ha presentato la comunicazione.
Venta interna de acciones ordinarias de XERS redujo la tenencia: El director John Johnson vendi贸 107.500 acciones ordinarias de Xeris Biopharma el 13/08/2025 a un precio medio ponderado de $7,3159 por acci贸n, quedando con 833.483 acciones de propiedad beneficiosa. El Formulario 4 indica la venta como una disposici贸n directa y se帽ala que el precio informado es un promedio ponderado que refleja m煤ltiples operaciones con precios entre $7,250 y $7,420. No se informan transacciones con derivados ni cambios adicionales en la propiedad indirecta. La presentaci贸n fue firmada por un apoderado en nombre de la persona que presenta el informe.
XERS 氤错喌欤� 雮措秬鞛� 毵る弰搿� 氤挫湢 歆�攵� 於曥唽: 鞚挫偓 John Johnson鞚� 2025-08-13鞐� Xeris Biopharma 氤错喌欤� 107,500欤茧ゼ 欤茧嫻 臧�欷戫弶攴犼皜瓴� $7.3159鞐� 毵る弰頃橃棳, 斓滌鞝侅溂搿� 833,483欤检潣 鞁れ唽鞙� 歆�攵勳潉 氤挫湢頃橁矊 霅橃棃鞀惦媹雼�. 鞝滌稖霅� Form 4電� 頃措嫻 毵る弰毳� 歆侅爲 觳橂秳鞙茧 旮办灛頃橁碃 氤搓碃霅� 臧�瓴╈潃 $7.250鞐愳劀 $7.420 靷澊鞚� 鞐煬 瓯半灅毳� 氚橃榿頃� 臧�欷戫弶攴犾瀯鞚� 氇呾嫓頃╇媹雼�. 韺岇儩靸來拡 瓯半灅雮� 臧勳爲 靻岇湢甓岇潣 於旉皜 氤�瓴届潃 氤搓碃霅橃 鞎婌晿鞀惦媹雼�. 鞝滌稖 靹滊電� 氤搓碃鞚胳潉 雽�鞁犿暣 鞙勳瀯 雼措嫻 氤�順胳偓臧� 靹滊獏頄堨姷雼堧嫟.
Vente interne d'actions ordinaires XERS a r茅duit la d茅tention聽: Le directeur John Johnson a vendu 107听500 actions ordinaires de Xeris Biopharma le 13/08/2025 au prix moyen pond茅r茅 de $7,3159 par action, le laissant avec 833听483 actions d茅tenues 脿 titre b茅n茅ficiaire. Le formulaire 4 indique la vente comme une cession directe et pr茅cise que le prix rapport茅 est une moyenne pond茅r茅e refl茅tant plusieurs transactions comprises entre $7,250 et $7,420. Aucune op茅ration sur d茅riv茅s ni modification suppl茅mentaire de la d茅tention indirecte n'est signal茅e. Le d茅p么t a 茅t茅 sign茅 par un mandataire au nom de la personne d茅clarante.
Insider-Verkauf von XERS-Stammaktien verringerte Beteiligung: Direktor John Johnson verkaufte am 13.08.2025 107.500 Xeris Biopharma-Stammaktien zu einem gewichteten Durchschnittspreis von $7,3159 je Aktie und bleibt mit 833.483 Anteilen wirtschaftlich berechtigt. Das Formular 4 f眉hrt den Verkauf als direkte Ver盲u脽erung auf und stellt klar, dass der gemeldete Preis ein gewichteter Durchschnitt aus mehreren Trades zwischen $7,250 und $7,420 ist. Es werden keine Derivatgesch盲fte oder weiteren 脛nderungen der indirekten Beteiligung gemeldet. Die Einreichung wurde von einem Bevollm盲chtigten im Namen der meldenden Person unterschrieben.
FAQ
What did the XERS Form 4 filed for John Johnson report?
At what prices were the XERS shares sold according to the filing?
Was the sale reported as direct or indirect on the XERS Form 4?
Does the Form 4 indicate any derivative transactions for XERS by this reporting person?
Who signed the Form 4 for the reporting person?
